日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England

更正:初级保健中对多种癌症检测(MCT)的偏好:英格兰全科医生和公众的离散选择实验

Buckell, John; Madyiwa, Nomalanga; Hayward, Gail; Middleton, Mark R; Hobbs, F D Richard; Buchanan, James; Tsiachristas, Apostolos; Nicholson, Brian D

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

LOGIC 2 研究的简明语言摘要:恩考拉非尼、比美替尼联合第三种药物治疗 BRAF V600 突变型黑色素瘤患者

Dummer, Reinhard; Sandhu, Shahneen; Miller, Wilson H Jr; Butler, Marcus O; Taylor, Matthew H; Heinzerling, Lucie; Blank, Christian U; Couselo, Eva Muñoz; Burris, Howard A 3rd; Postow, Michael A; Chmielowski, Bartosz; Middleton, Mark R; Berking, Carola; Hassel, Jessica C; Gesierich, Anja Heike; Mauch, Cornelia; Kleha, Joseph F; Polli, Anna; Harney, Allison S; di Pietro, Alessandra; Ascierto, Paolo A

Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials

评估接受切除术的 III/IV 期黑色素瘤患者的长期生存率:来自 CheckMate 238 和欧洲癌症研究与治疗组织 18071 试验的分析

Weber, Jeffrey S; Middleton, Mark R; Yates, Georgia; Sharpe, Daniel J; Kurt, Murat; Lobo, Maurice; Moshyk, Andriy; Vanderpuye-Orgle, Jacqueline; Mohr, Peter

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

RP1联合Nivolumab治疗晚期抗PD-1治疗失败的黑色素瘤(IGNYTE)

Wong, Michael K; Milhem, Mohammed M; Sacco, Joseph J; Michels, Judith; In, Gino K; Muñoz Couselo, Eva; Schadendorf, Dirk; Beasley, Georgia M; Niu, Jiaxin; Chmielowski, Bartosz; Wise-Draper, Trisha M; Bowles, Tawnya Lynn; Tsai, Katy K; Lebbé, Céleste; Gaudy-Marqueste, Caroline; Middleton, Mark R; Skolariki, Aglaia; Samson, Adel; Chesney, Jason A; VanderWalde, Ari M; Zakharia, Yousef; Harrington, Kevin J; Appleton, Elizabeth; Bommareddy, Praveen K; Zhu, Junhong; Viana, Marcus; Hou, Jeannie W; Coffin, Robert S; Robert, Caroline

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma

纵向基因组分析优化靶向治疗:BRAFV600突变转移性黑色素瘤患者的II期LOGIC 2试验结果

Dummer, Reinhard; Sandhu, Shahneen; Miller, Wilson H Jr; Butler, Marcus O; Taylor, Matthew H; Heinzerling, Lucie; Blank, Christian U; Muñoz-Couselo, Eva; Burris, Howard A 3rd; Postow, Michael A; Chmielowski, Bartosz; Middleton, Mark R; Berking, Carola; Hassel, Jessica C; Gesierich, Anja Heike; Mauch, Cornelia; Kleha, Joseph F; Polli, Anna; Harney, Allison S; di Pietro, Alessandra; Ascierto, Paolo A

Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England

初级保健中对多种癌症检测(MCT)的偏好:英格兰全科医生和公众的离散选择实验

Buckell, John; Madyiwa, Nomalanga; Hayward, Gail; Middleton, Mark R; Hobbs, F D Richard; Buchanan, James; Tsiachristas, Apostolos; Nicholson, Brian D

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

MEK1/2 抑制剂比美替尼联合 MET 抑制剂克唑替尼治疗 RAS 突变型晚期结直肠癌患者的 Ia/b 期研究 (MErCuRIC)

Aroldi, Francesca; Elez, Elena; André, Thierry; Perkins, Geraldine; Prenen, Hans; Popovici, Vlad; Gallagher, Peter; Houlden, Jennifer; Collins, Linda; Roberts, Corran; Rolfo, Christian; Di Nicolantonio, Federica; Grayson, Margaret; Boyd, Ruth; Bettens, Karolien; Delfavero, Jurgen; Coyle, Victoria; Lawler, Mark; Khawaja, Hajrah; Laurent-Puig, Pierre; Salto-Tellez, Manuel; Maughan, Tim S; Tabernero, Josep; Adams, Richard; Jones, Robert; Hennessy, Bryan T; Bardelli, Alberto; Peeters, Marc; Middleton, Mark R; Wilson, Richard H; Van Schaeybroeck, Sandra

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

一项针对晚期实体瘤患者的MEK1/2抑制剂PD-0325901联合c-MET抑制剂克唑替尼的Ia期研究

Gallagher, Peter; Rolfo, Christian; Elez, Elena; Taieb, Julien; Houlden, Jennifer; Collins, Linda; Roberts, Corran; André, Thierry; Lawler, Mark; Di Nicolantonio, Federica; Grayson, Margaret; Boyd, Ruth; Popovici, Vlad; Bardelli, Alberto; Carson, Robbie; Khawaja, Hajrah; Laurent-Puig, Pierre; Salto-Tellez, Manuel; Hennessy, Bryan T; Maughan, Tim S; Tabernero, Josep; Adams, Richard; Jones, Robert; Peeters, Marc; Middleton, Mark R; Wilson, Richard H; Van Schaeybroeck, Sandra

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma

Fianlimab(一种人淋巴细胞活化基因-3 (LAG-3) 单克隆抗体)联合 Cemiplimab 治疗晚期黑色素瘤的 I 期研究

Hamid, Omid; Lewis, Karl D; Weise, Amy; McKean, Meredith; Papadopoulos, Kyriakos P; Crown, John; Kim, Tae Min; Lee, Dae Ho; Thomas, Sajeve S; Mehnert, Janice; Kaczmar, John; Lakhani, Nehal J; Kim, Kevin B; Middleton, Mark R; Rabinowits, Guilherme; Spira, Alexander I; Yushak, Melinda; Mehmi, Inderjit; Fang, Fang; Chen, Shuquan; Mani, Jayakumar; Jankovic, Vladimir; Wang, Fang; Fiaschi, Nathalie; Brennan, Laura; Paccaly, Anne; Masinde, Sheila; Salvati, Mark; Fury, Matthew G; Kroog, Glenn; Lowy, Israel; Gullo, Giuseppe

Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis

前瞻性队列研究中收集并由英格兰和威尔士癌症登记处报告的癌症诊断数据的有效性和及时性:一项回顾性比较分析

Jackson, Ashley; Virdee, Pradeep S; Tonner, Sharon; Oke, Jason L; Perera, Rafael; Riahi, Kaveh; Luan, Ying; Hiom, Sara; Kumar, Harpal; Nandani, Harit; Kurtzman, Kathryn N; Huws, Dyfed; Allan, Dawn; Smits, Stephanie; McPhail, Sean; Parkes, Eileen E; Hobbs, F D Richard; Middleton, Mark R; Nicholson, Brian D